Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 21/1/2020
SIETES contiene 92882 citas

 1 a 20 de 74 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
van Eijk AM, Zulaika G, Lenchner M, Mason L, Sivakami M, Nyothach E, Unger H, Laserson KFPhillips-Howard PA. Menstrual cup use, leakage, acceptability, safety, and availability: a systematic review and meta-analysis. The Lancet Public Health 2019;4:1. [Ref.ID 103161]
3. Cita con resumen
Anónimo. Bayer to halt sales of Essure at the end of the year. DIA Daily 2018:23 de julio. [Ref.ID 102719]
5. Cita con resumen
Anónimo. Choice of contraceptives. Med Lett Drugs Ther 2015;57:127-32. [Ref.ID 99653]
6. Cita con resumen
Stam-Slob MC, Lambalk CB, van de Ree MA. Contraceptive and hormonal treatment options for women with history of venous thromboembolism. BMJ 2015;351:h4847. [Ref.ID 99595]
7. Cita con resumen
Herman AO. Long-acting contraceptives recommended as first choice for teens. Journal Watch 2014:30 de septiembre. [Ref.ID 97998]
8. Cita con resumen
Anónimo. Fibromyomes utérins hémorragiques. Adapter le traitement à chaque femme. Prescrire 2014;34:115-22. [Ref.ID 97129]
9. Cita con resumen
Anónimo. Bayer gains permanent contraceptive via conceptus buy. DIA Daily 2013:30 de abril. [Ref.ID 95296]
10.Tiene citas relacionadas
Espey E. Levonorgestrel intrauterine system - First-line therapy for heavy menstrual bleeding. N Engl J Med 2013;368:184-5. [Ref.ID 94747]
11.Tiene citas relacionadas Cita con resumen
Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J, ECLIPSE Trial Collaborative Group. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013;368:128-37. [Ref.ID 94744]
12. Cita con resumen
Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, Secura GM. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;366:1998-2007. [Ref.ID 93029]
13. Cita con resumen
Prabakar I, Webb A. Emergency contraception. BMJ 2012;344:61-4. [Ref.ID 92653]
14. Cita con resumen
Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012;344:e2990. [Ref.ID 92624]
15. Cita con resumen
Weiss-Smith S, Deshpande G, Chung S, Gogolak V. The FDA Drug Safety Surveillance Program: adverse event reporting trends. Arch Intern Med 2011;171:592. [Ref.ID 91171]
16. Cita con resumen
Anónimo. FDA warns drug companies about misleading statements. BMJ 2010;340:174. [Ref.ID 87703]
Rose SB. Pain and heavy bleeding with intrauterine contraceptive devices. BMJ 2007;335:410-1. [Ref.ID 81042]
19. Cita con resumen
Uhl K, Trontell A, Kennedy D. Risk minimization practices for pregnancy prevention: understanding risk, selecting tools. Pharmacoepidemiol Drug Saf 2007;16:337-48. [Ref.ID 79577]
Ornstein RM, Fisher MM. Hormonal contraception in adolescents: special considerations . Pediatr Drugs 2006;8:25-45. [Ref.ID 76687]
Seleccionar todas
 1 a 20 de 74 siguiente >>